SBIR Phase I: Biomimetic Adhesive for Seroma Prevention

SBIR 第一阶段：用于预防血清肿的仿生粘合剂

• 批准号: 1013156
• 负责人: Bruce Lee
• 金额: $ 15万
• 依托单位: Nerites Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2011-10-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1013156&HistoricalAwards=false
• 关键词: SBIR; Phase; Biomimetic; Adhesive; Seroma

This Small Business Innovation Research (SBIR) Phase I project proposes to develop a novel biomimetic adhesive for seroma prevention. Commercial bioadhesives have demonstrated mixed results as they are hampered by weak adhesive strengths, the need to mix precursors, and undesirable degradation rates. Thus, there continues to be an unmet clinical need for the development of a new and improved adhesive for seroma prevention. Nerites Corporation has developed adhesives that are synthetic mimics of the mussel adhesive proteins that can bind strongly to rocks and ship hulls in a wet, turbulent saline environment. Nerites? new series of adhesives requires no mixing or dissolution before use, and demonstrates significantly higher strength than currently available adhesives. Therefore, Nerites believes that these new materials will significantly improve clinical outcomes of many patients suffering from seroma. The broader/commercial impacts of this research are a potential reduction in seroma formation, a postoperative complication in many surgeries. Although the market for Nerites? adhesives may eventually expand to include any surgery where tissue planes are separated, the initial focus involves procedures where postoperative drains are the standard of practice. The benefits that result from reduced use of drains include increased patient comfort, shorter hospital stay, reduced chemotherapy duration, and decreased risk of wound infection. Therefore, Nerites? initially targeted surgical procedures include mastectomy, abdominoplasty, and open ventral hernia repair, with a combined estimate of more than 500,000 surgeries performed annually, where incidences of seroma formation can be as high as 59%.

这项小型企业创新研究（SBIR）一期项目旨在开发一种新型的仿生黏合剂，用于预防血肿。商业生物胶粘剂表现出好坏参半的结果，因为它们受到粘接强度弱、需要混合前体和不良降解率的阻碍。因此，对于开发一种新的和改进的用于预防血清肿的粘合剂，仍然存在未满足的临床需求。Nerites公司已经开发出一种胶粘剂，它是一种合成的模仿贻贝胶粘剂的蛋白质，可以在潮湿、湍流的盐水环境中与岩石和船体紧密结合。Nerites吗?新系列胶粘剂在使用前不需要混合或溶解，并且比目前可用的胶粘剂具有明显更高的强度。因此，Nerites认为这些新材料将显著改善许多血肿患者的临床结果。这项研究的更广泛/商业影响是可能减少血肿的形成，血肿是许多手术的术后并发症。尽管尼利特人的市场？粘接剂可能最终扩展到包括任何组织平面分离的手术，最初的重点涉及手术，术后引流是实践的标准。减少使用引流管的好处包括增加患者舒适度、缩短住院时间、缩短化疗时间和降低伤口感染风险。因此,Nerites吗?最初的针对性手术包括乳房切除术、腹部成形术和开放式腹疝修补术，估计每年进行的手术总数超过50万例，其中血清肿形成的发生率可高达59%。